RT Journal Article
SR Electronic
T1 COPD and concomitant arterial hypertension: The efficacy and safety of slow-release formulation of indapamide
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P3582
VO 44
IS Suppl 58
A1 Zara Nersesyan
A1 Svetlana Ovcharenko
A1 Tatyana Morozova
YR 2014
UL http://erj.ersjournals.com/content/44/Suppl_58/P3582.abstract
AB Treatment of COPD patients with concomitant arterial hypertension is associated with such significant complications as increasing of bronchial obstruction, hyperinflation, electrolytes balance changing and others.Aims: To investigate the efficacy and safety of slow-release (SR) formulation of indapamide in the treatment of COPD and concomitant hypertension.Methods: 33 out-patients with COPD and concomitant hypertension were recruited (27 male, mean age of 60.8±10.5, %FEV1 58.4±11.5%, index smoker 42.3±11.5). COPD duration was 10.5±3.5 years, hypertension duration was 14.3±7.4 years. All patients were received indapamide SR 1.5 mg/day for 3 months. Ambulatory blood pressure (BP) monitoring, spirometry and bodyplethysmography, serum potassium levels, respiratory symptoms (cough, sputum production, dyspnea severity) by CAT and MRC were assessed at baseline and after 3 month of treatment.Results: After 3 months of treatment it was noted: daily pattern of BP normalization (n=26), decreasing of the average diastolic BP at night-time (92.3±7.4 vs 71.4±3.8 mm Hg), decreasing of the average systolic (56.4±29.4 vs 30.4±21.5%) and diastolic (47.2±23.5 vs 31.6±21.7%) BP load at night-time, decreasing of the average night-time systolic BP variability (12.9±3.7 vs 9.5±2.5 mm Hg), p <0.05 for all. During all treatment period it wasn't revealed any significant changes in spirometry, bodyplethysmography parameters and plasma potassium levels.Conclusions: Using of indapamide SR in complex therapy of COPD and concomitant hypertension is efficacy and safety antihypertensive treatment that doesn't affect the existing hyperinflation and electrolytes balance.